Palod Distributors-Home Page
Home Page About Us Products Group Companies Scheme Our Videos Contact Us
News Detail
Jun. 14 2014
Industry at 8.1% for May 14 -------- Is Recovery on the anvil???
Industry at 8.1% for May 14 -------- Is Recovery on the anvil???

Jagdish Palodpaloddistributors.com


--- On Tue, 10/6/14, Hari Natarajan <hari.natarajan@aiocdawacs.com> wrote:
for web and
> From: Hari Natarajan <hari.natarajan@aiocdawacs.com>
> Subject: Industry at 8.1% for May 14 -------- Is Recovery on the anvil???
> To: industry1@aiocdawacs.com, industry2@aiocdawacs.com, industry3@aiocdawacs.com, industry4@aiocdawacs.com
> Date: Tuesday, 10 June, 2014, 1:23 AM
> Dear Partners,
> A Very Good Morning to all of
> you The month where a new changes
> happened around the country, the IPM also seems to have got
> a wind of change with growths registering on a higher end of
> a spectrum for the first time in the new fiscal at
> 8.1% -
> Growth in
> the month of May 2014 was at 8.1% (2.8% in Volumes in
> existing products and 3.6% from new launches). Growth from
> price increase was at 1.8% which was at 4.1% in May-13
> thereby signifying the impact of price cuts witnessed due to
> the implementation of the pricing policy.
>
> -
> The volume
> growths for the month of May 14 have translated into
> positive probably signaling the good months to come
> ahead-
> The
> quarter of Mar – May 14 also signals into positive
> growths which is in positive for the last 2 quarters
> now Major Highlights for
> Month of May 2014: Ø May Month
> Highlights:Ø The IPM clocked 6636 Crs in May
> 2014Ø The Indian Pharma Market grows at
> 8.1% for the month of May 2014Ø Hegde & Hegde becomes the
> 50th Biggest Corporate in the IPM
> Ø Corporates:Ø For the month of May 2014, amongst
> the top 10, Sun Pharma grew at 15.2% followed by Mankind at
> 13.3% and Lupin at 11.7%Ø 29 corporates have crossed the growth
> of IPM for the month of May 2014 amongst top 50
> Ø Amongst the top 50 Corporates,
> Akumentis has the highest growth of 54.1% followed by Ajanta
> at 45.0% & Biocon at 44.8%Ø Amongst the 11-20 ranked companies
> Macleods shows high growth at 26.7% followed by Biocon at
> 44.8% and Apex at 39.6%Ø Amongst the 50-60 ranked corporates,
> Apex grows at 39.6% followed by Troikaa at 30% & Panacea
> at 25.2%Ø Amongst the 61-75 ranked corporates,
> Corona grows at 41.1% followed by Pharmed at 28.8% and
> Serdia at 21.2% Ø Indian V/S
> MNCs:Ø Indian companies have grown at 10.5%
> versus 1.8% for MNCs in May 2014Ø Amongst the top 50 in MNCs MSD* grew
> the highest at 20.9%, followed by Merck at 13.9% and Janssen
> at 8.1%Ø Under the Non-NLEM category Indian
> Companies are growing at 10.4% whereas MNCs are growing at
> 1.6% Ø DPCO V/s Non DPCO
> Market:Ø The DPCO 2013 containing molecules
> market was at –11.5% whereas the non DPCO market grew
> by 8.0% resulting in an overall growth of 5.2% for May
> 2014Ø The DPCO 2013 portfolio for
> Pfizer degrew at 26.9%, GSK degrew at 19.5% & Ranbaxy
> degrew by 25.0%. Ø Therapy:Ø From therapy perspective 11 therapies
> have outgrown the IPM growth & 5 therapies have double
> digit growthsØ Respiratory Market grew at
> 11.8%, Gastrointestinal market grew at 7.2% whereas
> Anti-infectives grew at 2.5%Ø Anti-diabetic market grows at 17.2%
> & Cardiac at 7.8% in chronic businessØ Derma market grew by
> 12.9% Ø Regional
> Dynamics:Ø From regional perspective 13 regions
> have outgrown the IPM growthØ Madhya Pradesh market grew the
> highest at 17.8% followed by Vidarbha Market at 15.3%
> Ø No regions had negative growths in
> May 2014  Ø Molecules:Ø Glimepiride + Metformin becomes the
> No 1 Market growing at 34.4%, wheras Amoxycillin +
> Clavulanic Acid Market grows at 3.9%Ø The markets of Vitamin- D grew by
> 34.7%, Probiotic Microbes grew at 25.2%, Levocetirizine +
> Montelukast by 24.4%, Rosuvastain by 23.0%, Levetiracetam by
> 22.0%, & Telmisartan by 19.4%
> Ø Brands:Ø Lantus grows at 26.1% amongst the top
> 10 Brands and adds up 9 ranks to be the 7th
> Biggest Brand in the IPM for the month of May
> 2014Ø Amongst the Brands who have gained
> ranks include Glycomet-GP (+7), Liv-52 (+7), Skinlite
> (+10), Zincovit, Galvus Met (+21), Gluconorm-G (+39),
> Jalra-M (+51), Telma (+16), Orofer – XT (+13),
> Susten (+32), Pan-D (+10), Dolo (+44), Zerodol-P (+66),
> Dynapar AQ (+90) amongst top 100 BrandsØ Amongst the top brands in the
> IPM, Glycomet GP (23.7%), Lantus (26.1%), Galvus
> Met (45.1%), Skinlite (24.1%), Telma (22.4%),
> Zincovit (32.0%) Liv-52 (17.0%) grew fastest amongst top 25
> Brands over May-13 Ø New
> Launches in IPM:Ø Total 160 Brands launched in May
> 2014Ø MY HMG, HYLASTO ONE, LUMIA are the
> top NIs for the month of May 2014 Therapy Perspective:
> Two New Corporates – Mylan
> & Besins Healthcare have started featuring in the May
> 2014 Database

 

With Bonus Units at Full Value   Without Bonus Units
Rank MAT May-14 May-14 Val in Crs Rank MAT May -14 May-14
MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR% CORPORATE MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR%
    76567 100.00 5.9 6636 100.00 8.1 IPM     73629 100.00 5.9 6397 100.00 8.7
1 1 4893 6.39 3.8 414 6.44 4.8 Abbott + Abbott HC + Novo `1 1 4794 6.51 3.5 407 6.36 5.2
2 2 4168 5.44 15.4 377 5.34 15.2 Sun Pharma 2 2 4073 5.53 14.4 370 5.78 15.2
3 3 3809 4.97 6.2 326 4.97 6.8 Cipla `2 3 3572 4.85 9.0 307 4.80 10.3
4 4 3363 4.39 6.3 281 4.39 4.3 Zydus + Biochem 3 4 3143 4.27 6.1 264 4.12 5.7
5 6 2836 3.70 -3.6 233 3.98 -4.7 Ranbaxy `3 7 2743 3.73 -3.6 225 3.52 -4.7
6 5 2727 3.56 5.4 243 3.50 13.3 Mankind `5 9 2306 3.13 6.9 208 3.25 16.9
7 8 2710 3.54 -15.6 227 4.02 -7.8 Glaxo 4 6 2675 3.63 -14.9 226 3.53 -6.2
8 9 2673 3.49 9.9 226 3.39 8.3 Alkem + Cachet + Indchemie 5 8 2483 3.37 9.7 212 3.31 10.0
9 7 2581 3.37 11.7 230 3.36 11.7 Lupin `4 5 2524 3.43 11.6 226 3.53 12.1
10 11 2226 2.91 3.0 189 2.95 4.0 Pfizer  6 11 2176 2.95 3.3 185 2.89 4.6
11 12 2162 2.82 15.0 183 2.65 12.9 Emcure + Zuventus `6 12 2097 2.85 15.3 178 2.78 13.5
12 10 2056 2.69 11.5 198 2.55 26.7 Macleods 7 10 1927 2.62 11.2 186 2.90 26.8
13 13 1926 2.52 0.3 175 2.65 7.7 Sanofi `7 13 1890 2.57 0.0 172 2.68 7.6
14 14 1909 2.49 7.0 168 2.55 7.4 Intas 8 14 1884 2.56 6.4 166 2.60 7.7
15 15 1877 2.45 14.7 164 2.17 23.1 Aristo `8 15 1654 2.25 11.9 143 2.23 20.5
16 18 1667 2.18 15.7 131 1.89 13.6 Glenmark 9 18 1619 2.20 15.3 128 2.00 13.4
17 16 1635 2.14 5.7 144 2.16 8.9 Dr. Reddys `9 16 1602 2.18 4.9 141 2.21 8.8
18 17 1572 2.05 9.3 139 2.15 5.7 Micro + Bal 10 17 1503 2.04 9.9 134 2.09 6.3
19 21 1407 1.84 9.1 118 1.87 3.1 USV `10 21 1401 1.90 9.0 118 1.84 3.4
20 19 1394 1.82 14.0 127 1.79 15.1 Torrent 11 19 1370 1.86 13.8 124 1.94 14.5
21 20 1372 1.79 20.4 124 1.59 27.8 IPCA `11 20 1305 1.77 20.0 120 1.87 29.4
22 22 1222 1.60 3.0 102 1.53 8.6 Wockhardt 12 22 1197 1.63 2.7 100 1.56 8.7
23 23 1133 1.48 -1.3 94 1.55 -1.4 Novartis `12 23 1092 1.48 -0.6 91 1.42 0.4
24 24 1056 1.38 10.5 86 1.23 13.4 Alembic 13 24 1023 1.39 11.0 83 1.30 14.3
25 25 812 1.06 2.3 72 1.13 2.8 FDC `13 25 790 1.07 2.2 69 1.08 3.2
26 27 793 1.04 8.2 70 0.98 16.1 Unichem 14 27 776 1.05 7.5 68 1.06 16.1
27 26 784 1.02 7.7 70 0.95 19.6 MSD + Fulford + Organon `14 26 774 1.05 7.6 69 1.07 18.8
28 28 616 0.80 11.4 55 0.83 7.7 Cadila 15 28 594 0.81 11.2 53 0.83 7.6
29 29 592 0.77 5.3 50 0.72 13.2 Indoco Remedies 16 30 551 0.75 5.6 47 0.73 13.4
30 31 567 0.74 11.6 48 0.69 13.5 Franco `16 31 546 0.74 11.0 46 0.72 13.3
31 30 566 0.74 24.1 50 0.72 13.4 Eris `15 29 563 0.76 23.9 50 0.77 13.3
32 32 470 0.61 3.0 44 0.63 14.1 Himalaya 17 32 468 0.64 2.6 44 0.68 13.8
33 34 465 0.61 8.9 42 0.60 13.9 Merck `17 34 454 0.62 7.5 41 0.64 12.6
34 43 429 0.56 -41.4 30 0.97 -49.8 Elder 18 42 413 0.56 -39.8 29 0.46 -47.7
35 37 423 0.55 1.5 35 0.50 14.2 Blue Cross `19 37 389 0.53 3.5 32 0.50 13.5
36 33 405 0.53 11.0 43 0.65 6.8 JB Chemicals 19 33 389 0.53 10.8 41 0.64 6.1
37 40 395 0.52 16.7 32 0.51 0.9 Astrazeneca `18 39 391 0.53 15.8 31 0.49 0.5
38 39 383 0.50 -10.7 32
eXpert Solution by
North South Technologies Pvt. Ltd.